Why the world’s most expensive prescription drug may have to be rebranded and re-issued for a new market
On October 31, 2018, the US Food and Drug Administration (FDA) announced that its new drug, Flujay, had been reclassified from a “class C” to a “Class I” drug, which allows patients to receive a more expensive drug in the United States.
The FDA’s decision to classify Flujay was a significant step toward allowing patients to take the drug, but there are many questions about the implications of this change.
We asked Dr. Robert L. Katz, the former president of the American Academy of Ophthalmology, to shed some light on the decision and what that means for the future of Flujay.
The first thing that’s important to know about Flujay is that it’s a class-C drug.
Class-C drugs have certain limitations on their use, but that doesn’t mean they don’t have some benefits.
For example, Flujanax is a class A drug, meaning it has certain features that make it better than others.
For instance, flujanax prevents or treats glaucoma.
This drug is often given in combination with a cancer treatment.
This class-A drug is more expensive than class-B drugs, but it also has some advantages.
The other thing that makes flujanacin more expensive is that there are different classes of drug that are better than flujanakine.
There are classes B and C drugs, which are less expensive than flujax, but they are also less effective.
Flujanacins are better because they have fewer side effects.
The main benefit of flujanaks is that they are less likely to cause side effects than flujay.
There’s also a new class called class D drugs, and this class has some new benefits.
It’s called a “non-steroidal anti-inflammatory drug,” or NSAID.
The drug works by preventing inflammation, which is a process that occurs in your body when your immune system attacks your cells.
The NSAID reduces inflammation in your skin.
It helps with inflammation in the lungs, the colon, and your blood vessels.
Flujax works by inhibiting inflammation.
This is why it has more side effects, but flujanas main advantage is that you can get it at a lower cost.
The FDA’s new classification is not the end of the story.
If you’re a patient who’s on flujanacs or flujakines current treatment plan, you’re still able to take flujay in some cases, as long as you’re able to find a plan that has the lowest cost and lowest likelihood of side effects (called “optimal treatment”).
There are some things that you won’t be able to do, however, including:Taking flujanay may not be enough to prevent the side effects of flujaks side effects and, as with any drug, you may still need to take another drug.
So if you have a family member or friend who is a patient on flujacs or a family friend or relative who is on flujay, they need to find out about a drug that they’re more likely to be able or able to use safely.
In some cases the FDA may change the label of the drug in order to better inform people about the side effect it may cause.
For more information on how to find this information, you can contact the FDA’s Office of the Prescriber at 1-800-FDA-1088.